Employing Amplatzer Occluder® in Cardiac Free Wall Rupture Repair: A Scoping Study

Pramod Theetha Kariyanna¹, Ashkan Tadayoni¹, Amog Jayarangaiah², Sudhanva Hegde¹, Apoorva Jayaranagaiah³, Moro O. Salifu¹, Isabel M. McFarlane¹,*

¹Department of Internal Medicine, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, U.S.A.
²Trinity School of Medicine, 925 Woodstock Road, Roswell, GA 30075, U.S.A.
³Department of Internal Medicine, Albert Einstein College of medicine/ Jacobi Medical Center, Bronx, N.Y., U.S.A.

Abstract

Cardiac free wall rupture (CFWR) is an uncommon complication of myocardial infarction, cardiac-based procedures, and blunt chest trauma. Cardiac tamponade and shock which occurs as a result of CFWR results in a high mortality rate. Despite the high mortality rate, there is a window of opportunity for intervention in selected patients with acute or subacute free wall rupture. Hence, prompt diagnosis and intervention are key to prevent cardiac tamponade and death. Even though emergency surgical repair is the standard treatment for the CFWR, the catheter-based procedure has provided an alternative treatment option, especially, in the high-risk surgical patients. For instance, Amplatzer occluder® (AO), a device which is used in repairing congenital septal wall defect, is being used as an alternative method of treatment in CFWR. In this systemic review, we assessed the 19 cases of CFWR occurring after invasive cardiac procedures who underwent repair with the utilization of AO®. The study shows that the successful rate of percutaneous closure of CFWR was 84.3% (16/19) with a mortality rate of 15.7% (3/19) in this cohort. Therefore, the in-hospital mortality rate of CFWR closure is comparable with the average in-house mortality rate of emergency surgical repair which is 14%. Furthermore, we found that AO® placement technique has a lower mortality rate compared to the other less-invasive methods such as percutaneous intrapericardial fibrin-glue injection which has a mortality rate of 25%. In conclusion, employing AO® in CFWR repair not only serves as the treatment of choice in the high-risk surgical candidates but could also be applied as an alternative method in the general population. However, further studies are required to assess the outcome and mortality rate of using A® in CFWR to provide us with a more consistent and accurate data.

Keywords

Amplatzer occluder; Cardiac free wall rupture; acute myocardial complication; catheter-based procedure; surgical repair mortality

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

*Corresponding author: Isabel.McFarlane@downstate.edu.
1. Introduction

Cardiac free wall rupture (CFWR) is a rare medical condition which is mostly related to acute myocardial infarction (MI) [1,2]. Even though the prevalence of postinfarction CFWR is only 2–4%, the autopsy studies reveal that it is associated with 7–24% of post MI deaths [3]. In addition to MI, CFWR may occur following cardiac-based procedure and blunt trauma with the prevalence of 0.5–1% and 0.3–1.1%, respectively [2,4].

There are several identified clinical forms of CFWR [5]. The catastrophic form which is the most common one is the sudden rupture of free wall with massive hemorrhage into pericardial space followed by cardiac tamponade and death [5,6]. However, in the subacute form which includes one third of the cases, the course is gradual with slow progressive bleeding into the pericardium [5]. Cardiac pseudoaneurysm, an uncommon form of CFWR, generally is a consequence of myocardium rupture which is contained within a portion of pericardium, therefore the wall of the pseudoaneurysm consists of pericardium and fibrotic tissue [5,7].

Despite the high fatality rate of CFWR, with more than 90% of the patients of developing cardiac tamponade, there is a constrained time period for intervention in patients with acute or subacute wall rupture [8,9]. Hence, prompt diagnosis and proper closure is crucial to prevent cardiac tamponade and death. The availability of point of care echocardiography has resulted in an increased and prompt recognition of cases of CFWR [5]. The standard treatment is emergency surgical repair which is categorized into two different techniques; sutureless repair and sutured repair with the peri-procedural mortality rate of 14% and 13.8%, respectively [8].

Recently, catheter-based procedures have provided alternative treatment options, especially, in high-risk surgical candidates [4]. For instance, transcatheter closure with Amplatzer occluder® is an established method of sealing congenital septal defects [10]. The AO® consists of two self-expandable uniformly sized discs of polyester material (Nitinol wire) that promotes occlusion and tissue growth. Once the area of the rupture wall has been located, the first disc is deployed on the outer aspect of the ruptured cardiac wall; the connecting waist centers the device and allows the second polyester disc to be deployed on the endocardial size of the cardiac wall defect. The AO® is available in a wide range of sizes and can treat defects from 3 mm up 38 mm. Even though the AO related thrombosis is uncommon, the complication might be serious [11]. Therefore, optimal antiplatelet treatment with the proper echocardiographic follow up must be performed, and once the device-related thrombosis is detected, advancing the treatment with therapeutic anticoagulation with aggressive follow-up is inevitable [12]. We performed a systematic review of studies that used AO® in treating CFWR secondary to myocardial infarction, cardiac-based procedure, and trauma in the high-operative risk patients [12].

2. Materials and Methods

A comprehensive computer-based literature search was conducted using PubMed, Google Scholar, CINAHL, Cochrane CENTRAL and Web of Science databases. Our search
keywords “cardiac free wall rupture, ventricular free wall rupture, myocardial infarction, cardiac-based procedure, trauma, Amplatzer Occluder®, transcatheter closure, percutaneous closure” were used to determine cases of CFWR which was treated with percutaneous closure method. This extensive systematic review includes articles from May 2006 until November 2019. The reference list of each article was reviewed and checked for relevant cases.

Only studies using percutaneous closure in treating the cohorts with CFWR were included in this systematic review. We excluded the non-English and non-human studies. In addition, all meta-analysis, review articles, and abstracts were excluded from this study.

Data reviewed included demographic data, cardiovascular risk factor, cause of free wall rupture, location of the perforation, size of Amplatzer, complication of the percutaneous closure and outcome.

3. Results

While 1,810 articles were identified through applying the keywords in database searching, given the title and eligibility criteria, only 24 articles were qualified to be included in this study. After assessing the full-text of the eligible articles, 17 of studies were selected for final analysis.

A total of 19 patients with the median ± standard deviation (SD) age of 73 ± 16.5 years and a predominance of female gender (52%) were identified (Table 1). The most common cardiovascular risk factors in the study population was coronary artery disease with the prevalence of 68%. The rest of the comorbidities include: hypertension (15%), heart failure (15%), diabetes (5%), and obesity (5%). Invasive cardiac-based procedure was accountable for free wall rupture in 89.4% of the individuals. The other mechanisms involved in CFWR are myocardial infarction and trauma (Table 2). The chamber involved in CFWR was as follows: left ventricle (65%), right ventricle (15%), right atrium (15%), and atrial appendage of left atrium (5%) (Table 1). Amplatzer occluder® was used to fix the free wall rupture in all 19 cases; in 73% (14/19) of patients the AO® percutaneous closure procedure was done without any complication. However, complication during the AO® procedure was reported in 26% (5/19) of cases with the death rate of 60% (3/5) within the cohort who experienced complications. In addition, one of the patients with the successful AO® placement died seven days later due to severe pulmonary contusion and ribs fracture following a traumatic chest injury. Therefore, the successful rate of percutaneous closure of CFWR was 84.3% (16/19) with the mortality rate of was 15.7% (3/19) in this cohort (Table 3).

4. Discussion

To the best of our knowledge, the current systematic review is the first study to assess the mortality rate and complications of employing Amplatzer occluder® in the non-operative management of individuals with CFWR.

CFWR is an uncommon but fatal complication of myocardial infarction with a mortality rate of 39–77% [8,11]. Additionally, CFWR may occur as a complication of cardiac-
based procedure or trauma [4,12]. Significant advancements and increasing use of cardiac-based procedure, such as cardiac catheterization, patent foramen ovale closure, left atrial appendage closure, defibrillator placement, and pericardiocentesis has resulted in an increased incidence of CFWR [4,13–25].

Early detection and prompt intervention is crucial to prevent cardiac tamponade and death [26]. Transthoracic echocardiography plays an important role in detecting pericardial effusion and right ventricular compression which are the most relevant findings in CFWR [8,27]. Detecting echogenic masses in the pericardial spaces significantly enhances both sensitivity and specificity for hemorrhagic effusion. Pericardiocentesis may confirm final diagnosis [8].

Commonly, surgical repair is the definitive treatment for CFWR [28]. There are mainly two different methods of surgery reported in literature; sutureless and sutured repair. The major differentiation between the two groups is employing suture to repair free wall rupture [8]. Matteucci et al [8] reported that the average mortality rate of patients who underwent either type of the surgery was 14%. Recently, less-invasive method, called percutaneous intrapericardial fibrin-glue injection, has been performed in the patients with ventricular free wall rupture with a mortality rate of 25% [29,30]. Terashima et al [31] reported that this less-invasive procedures could apply for the high-risk surgical cases. In accordance with this concept, we performed a systematic review of the cases who underwent AO® placement as a treatment of CFWR that had occurred in its majority as an adverse event of invasive cardiac procedures.

In the current review, the AO® post-procedure complications were reported in 26% of the cases. Pericardial effusion was the most common complication in this cohort with the prevalence of 15.7%, with 2 patients experiencing cardiac tamponade (Table 3). In addition, our analysis revealed that the in-hospital mortality rate of CFWR closure with AO is 15.7% which is comparable with the mortality rate associated with surgical repair, which is the stand of care [8]. Our study findings reaffirm other studies that less invasive percutaneous procedures are a safe and effective alternative in CFWR repair [31]. Additionally, the use of AO® technique has a comparatively lower mortality rate compared to the other less-invasive methods such as percutaneous intrapericardial fibrin-glue injection which report a mortality rate of 25% [8]. Apart from its role in high risk patients, the AO® technique may be considered as a ‘bail-out’ procedure in CFWR. Further evidence is required to investigate its utility in otherwise low risk surgical population.

5. Limitations

The major limitation of this systemic review is that it may be subject to selection bias as it is a review focusing on the published literature that report the use of AO® for CFWR that occurred as a complication during an invasive cardiac procedure. Additionally, there are a limited number of cases which used Amplatzer occluder in the treatment of CFWR. All of the studies were either case reports or case series which means there is no control group to compare the procedure more accurately. We only evaluated the in-hospital mortality rate due to lack of information regarding the long-term follow-up of the patients.
6. Conclusion

CFWR carries a high mortality rate. It is an uncommon complication of MI, cardiac procedures, and blunt trauma. The standard treatment of CFWR is emergency surgical repair. The current systematic review demonstrates that less invasive procedures such as using AO in CFWR repair might have the same mortality rate as surgical repair. Therefore, employing AO in the CFWR repair could be a potentially life-saving alternative, especially in patients who are not fit to undergo surgery. However, further studies are required to evaluate the outcome and mortality rate of using AO in the CFWR repair to provide us with more consistent and accurate data.

Acknowledgements

This work is supported, in part, by the efforts of Dr. Moro O. Salifu M.D., M.P.H., M.B.A., M.A.C.P., Professor and Chairman of Medicine through NIH Grant No. S21MD012474.

References

[1]. Figueras J, Cortadellas J, Soler-Soler J. Left ventricular free wall rupture: clinical presentation and management. Heart. 2000; 83(5): 499–504. [PubMed: 10768896]
[2]. Dar T, Yarlagadda B, Gunasekaran P, Lakikreddy D, Wiley MA. Successful Percutaneous Closure of Traumatic Right Ventricular Free Wall Rupture Using Amplatzer Vascular Plug Devices. J Atr Fibrillation. 2018; 11(2): 2095. [PubMed: 30505386]
[3]. McMullan MH, Maples MD, Kilgore TL Jr, Hindman SH. Surgical experience with left ventricular free wall rupture. The Annals of thoracic surgery. 2001; 71(6): 1894–9. [PubMed: 11426765]
[4]. Vignati G, Bruschi G, Mauri L, Annoni G, Frigerio M, Martinelli L, et al. Percutaneous device closure of iatrogenic left ventricular wall pseudoaneurysm. The Annals of thoracic surgery. 2009; 88(4): e31–e3. [PubMed: 19766773]
[5]. Shiyovich A, Nesher L. Contained left ventricular free wall rupture following myocardial infarction. Case Rep Crit Care. 2012; 2012.
[6]. Slater J, Brown RJ, Antonelli TA, Menon V, Boland J, Col J, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Journal of the American College of Cardiology. 2000; 36(3 Supplement 1): 1117. [PubMed: 10985714]
[7]. Harpaz D, Kriwisky M, Cohen AJ, Medalion B, Rozenman Y. Unusual form of cardiac rupture: Sealed subacute left ventricular free wall rupture, evolving to intramyocardial dissecting hematoma and to pseudoaneurysm formation— A case report and review of the literature. Journal of the American Society of Echocardiography. 2001; 14(3): 219–27. [PubMed: 11241018]
[8]. Matteucci M, Fina D, Jiritano F, Blankestijn WM, Raffa GM, Kowalewski M, et al. Sutured and sutureless repair of postinfarction left ventricular free-wall rupture: a systematic review. European Journal of Cardio-Thoracic Surgery. 2019; 56(5): 840–8. [PubMed: 30938415]
[9]. Stolt V, Cook S, Raber L, Wani S, Garachamani A, Vogel R, et al. Amplatzer Septal Occluder to treat iatrogenic cardiac perforations. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions 2012; 79(2): 263–70.
[10]. Mullasari AS, Umesan CV, Krishnan U, Srinivasan S, Ravikumar M, Raghuaraman H. Transcatheter closure of post—myocardial infarction ventricular septal defect with Amplatzer septal occluder. Catheterization and Cardiovascular Interventions. 2001; 54(4): 484–7. [PubMed: 11747185]
[11]. Roth CP, Qarmali M, Litovsky SH, Brott BC. Myocardial rupture after small acute myocardial infarction in the absence of coronary artery disease. Cardiovascular Pathology. 2018; 37: 26–9. [PubMed: 30223140]
[12]. Dar T, Yarlagadda B, Gunasekaran P, Lakhireddy D, Wiley MA. Successful Percutaneous Closure of Traumatic Right Ventricular Free Wall Rupture Using Amplatzer Vascular Plug Devices. J Atr Fibrillation. 2018; 11(2): 2095. [PubMed: 30505386]

[13]. Vogel R, Windecker S, Meier B. Transcatheter repair of iatrogenic left ventricular free-wall perforation. Catheterization and Cardiovascular Interventions. 2006; 68(6): 829–31. [PubMed: 17086537]

[14]. Gladding Patrick A, Ruygrok Peter N, Greaves Sally C, Gerber Ivor L, Hamer Andrew W. Percutaneous Closure of a Left Ventricular Free-Wall Rupture Site. Circulation. 2006; 113(18): e748–e9. [PubMed: 16684866]

[15]. Chiam PTL, Schneider LM, Ruiz CE. Cardiac perforation during patent foramen ovale closure sealed with an amplatzer PFO occluder. J Invasive Cardiol. 2008; 20(12): 665–8. [PubMed: 19057033]

[16]. Saxena A, Karmakar S, Narang R. Successful Percutaneous Device Closure of Right Ventricular Perforation During Pericardiocentesis. JACC: Cardiovascular Interventions. 2016; 9(22): e221. [PubMed: 28102822]

[17]. Eshtehardi P, Garachemani A, Meier B. Percutaneous closure of a postinfarction ventricular septal defect and an iatrogenic left ventricular free-wall perforation using two Amplatzer muscular VSD occluders. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. 2009; 74(2): 243–6. [PubMed: 19405157]

[18]. Stolt V, Cook S, Räber L, Wani S, Garachamani A, Vogel R, et al. Amplatzer septal occluder to treat iatrogenic cardiac perforations. Catheterization and Cardiovascular Interventions. 2012; 79(2): 263–70. [PubMed: 22131255]

[19]. Elbey MA, Ertas G, Bacaksiz A, Goktekin O, Erdogan E. Transcatheter closure of left ventricular free wall rupture with Amplatzer atrial septal defect occluder. Clinical Research in Cardiology. 2013; 102(4): 313–4. [PubMed: 23196987]

[20]. Acharya D, Nagaraj H, Misra VK. Transcatheter closure of left ventricular pseudoaneurysm. J Invasive Cardiol. 2012; 24(6): E111–4. [PubMed: 22684390]

[21]. Vatan B, Akdemir R, Cakar M, Gunduz H, Varim C. Immediate Primary Transcatheter Closure of Left Ventricular Free Wall Rupture after Myocardial Infarction. Cardiology. 2013; 125(2): 82–5. [PubMed: 23689834]

[22]. Meier B, Tarbine SG, Costantini CR. Percutaneous management of left atrial appendage perforation during device closure. Catheterization and Cardiovascular Interventions. 2014; 83(2): 305–7. [PubMed: 23674434]

[23]. Tsai IC, Lin M-C, Jan S-L, Fu Y-C. Multidetector Row Computed Tomography for Percutaneous Closure of a Left Ventricular Free Wall Rupture After Myocardial Infarction. JACC: Cardiovascular Interventions. 2015; 8(11): e175–e6. [PubMed: 26404207]

[24]. Mohamed E, Telila T, Osaki S, Jacobson K. Percutaneous closure of left ventricle pseudoaneurysm using 3D printed heart model for procedure planning: A novel approach. Catheterization and Cardiovascular Interventions. 2019; 94(6): 874–7. [PubMed: 31313478]

[25]. Singleton MJ, Brunetti R, Schoenfeld MH, Bhave PD, Zhao DX, Whalen SP. Lead extraction complicated by right ventricular pseudoaneurysm: Percutaneous closure with septal occluder device. HeartRhythm Case Reports. 2019; 5(11): 542–4. [PubMed: 31890569]

[26]. Holmes DR, Nishimura R, Fountain R, Turi ZG. Iatrogenic Pericardial Effusion and Tamponade in the Percutaneous Intracardiac Intervention Era. JACC: Cardiovascular Interventions. 2009; 2(8): 705–17. [PubMed: 19695538]

[27]. Kariyanna PT, Jayarangaiah A, Pedalino R, Hegde S, Marmur JD, Shenoy A, et al. Esophageopercardial Fistula Induced Community Acquired Methicillin Resistant Staphylococcus Aureus (CA-MRSA) Cardiac Tamponade - A Rare Case Report and Literature Review. Am J Med Case Rep. 2018; 6(6): 109–13. [PubMed: 30079377]

[28]. Pollak H, Diez W, Spiel R, Enenkel W, Mlczoch J. Early diagnosis of subacute free wall rupture complicating acute myocardial infarction. European heart journal. 1993; 14(5): 640–8. [PubMed: 8508857]
[29]. Murata H, Masuo M, Yoshimoto H, Toyama J, Shimada M, Shimamura Y, et al. Oozing type cardiac rupture repaired with percutaneous injection of fibrin-glue into the pericardial space. Japanese circulation journal. 2000; 64(4): 312–5. [PubMed: 10783056]

[30]. Joho S, Asanoi H, Sakabe M, Nakagawa K, Kameyama T, Hirai T, et al. Long-term usefulness of percutaneous intrapericardial fibrin-glue fixation therapy for oozing type of left ventricular free wall rupture. Circulation journal. 2002; 66(7): 705–6. [PubMed: 12135143]

[31]. Terashima M, Fujiwara S, Yaginuma GY, Takizawa K, Kaneko U, Meguro T. Outcome of percutaneous intrapericardial fibrin-glue injection therapy for left ventricular free wall rupture secondary to acute myocardial infarction. The American journal of cardiology. 2008; 101(4): 419–21. [PubMed: 18312750]

[32]. Harrison W, Ruygrok PN, Greaves S, Wijesinghe N, Charleson H, Wade C, et al. Percutaneous Closure of Left Ventricular Free Wall Rupture with Associated False Aneurysm to Prevent Cardioembolic Stroke. Heart, Lung and Circulation 2008; 17(3): 250–3.

[33]. Alshehri HZ, Momenah TS, AlBaradai A, Sallam A, Alassal MA, Lawand S. Successful percutaneous closure of post myocardial infarction left ventricular ruptured pseudoaneurysm after failed surgical repair. Journal of Cardiology Cases. 2014; 9(4): 154–7. [PubMed: 30546789]
Table 1.

Cases of percutaneous closure of cardiac free wall rupture included in this study

| Year, author | Etiology of perforation | Indication of procedure/event that cause free wall perforation | Location of the perforation | Symptoms post perforation |
|--------------|-------------------------|---------------------------------------------------------------|----------------------------|--------------------------|
| 1 2006, Vogel [13] | Cardiac catheterization | HFrEF | LV£ | Chest pain |
| 2 2006, Gladin [14] | Cardiac catheterization | Enlarging LV pseudoaneurysm | LV | - |
| 3 2007, Harrison [32] | Post MI free wall rupture | | LV (posterolateral wall) | - |
| 4 2008, Chiam [15] | PFO closure | Cerebrovascular accident | RA£ | - |
| 5 2009, Vignati [4] | CRT | HFrEF | LV | - |
| 6 2009, Alshehri [33] | Cardiac catheterization | LV pseudoaneurysm repair | LV | - |
| 7 2009, Eshtehardi [17] | Cardiac catheterization | VSD closure post LADH MI | LV | - |
| 8 2011, Stolt [18] | Cardiac catheterization | Percutaneous closure of port-a-cath related RA perforation | RA | Retrosternal discomfort |
| 9 2011, Stolt [18] | Cardiac catheterization | Tandem heart placement during cardiogenic shock | RA | - |
| 10 2011, Stolt [18] | Cardiac catheterization | Aortic stenosis | LV | - |
| 11 2012, Acharya [20] | Cardiac catheterization | Percutaneous closure of LV pseudoaneurysm | LV | Chest pain, dyspnea |
| 12 2012, Elbey [19] | Cardiac catheterization | STEMI in inferior and lateral leads | LV (apex) | - |
| 13 2013, Vatan [21] | Cardiac catheterization | Complete occlusion of the right coronary artery | LV (inferior wall) | Chest pain, sweating, blurred vision |
| 14 2014, Meier [22] | Percutaneous LAA closure | LAA closure | LAA | - |
| 15 2015, Tsai [23] | Cardiac catheterization | Percutaneous closure of LV pseudoaneurysm | LV | Dyspnea |
| 16 2016, Saxena [16] | Percardiocentesis | Cardiac tamponade | RVv | - |
| 17 2018, Dar [12] | Trauma | - | RV (apical) | - |
| 18 2019, Mohammed [24] | Cardiac catheterization | Closure of LV pseudoaneurysm | LV | Chest pain, dyspnea |
| 19 2019, Singleton [25] | RV lead extraction | Recalled RV lead | RV | - |

CRT= Cardiac resynchronization therapy; HFrEF= Heart failure with reduced ejection fraction; LAA= Left atrial appendage; HLAD = Left anterior descending artery; £LV = Left ventricle; MI = myocardial infarction; PFO = Patent foramen ovale; RA = right atrium; RV = Right ventricle; VSD = ventricular septal defect; a STEMI= ST elevation myocardial infarction.
Table 2.

Etiology of cardiac free wall rupture

| Mechanism                | n* (percentage) |
|--------------------------|-----------------|
| Cardiac catheterization  | 12 (63.1%)      |
| PFO closure              | 1 (5.2%)        |
| Percutaneous LAA closure | 1 (5.2%)        |
| Pericardiocentesis       | 1 (5.2%)        |
| RV lead extraction       | 1 (5.2%)        |
| CRT-D placement         | 1 (5.2%)        |
| Myocardial infarction    | 1 (5.2%)        |
| Trauma                   | 1 (5.2%)        |

n* = number of patients  
PFO = patent foramen ovale  
LAA = left atrial appendage  
RV = right ventricle  
CRT = cardiac resynchronization therapy defibrillator
| Year, author | Size of Amplatz (mm) | Complications related to Amplatz occluder placement | Proper intervention after Amplatz placement complication | Death |
|-------------|---------------------|-----------------------------------------------------|--------------------------------------------------------|-------|
| 1 2006, Vogel [13] | 4                   | -                                                   | -                                                      | -     |
| 2 2006, Gladin [14] | 12                  | -                                                   | -                                                      | -     |
| 3 2007, Harrison [32] | 18                  | -                                                   | -                                                      | -     |
| 4 2008, Chian [15] | 18                  | -                                                   | -                                                      | -     |
| 5 2009, Vignati [4] | 5                   | -                                                   | -                                                      | -     |
| 6 2009, Alshehri [33] | 14                  | -                                                   | -                                                      | -     |
| 7 2009, Eshtehardi [17] | 10                 | -                                                   | -                                                      | -     |
| 8 2011, Stolt [18] | 4                   | Thrombus attached to device nipple | tPAa was given due failure of aspiration of thrombus through the sheath. | -     |
| 9 2011, Stolt [18] | 5                   | Tamponade developed 7 days after procedure | Treatment with surgical revision. ASO was in a stable position without evidence of leakage. | -     |
| 10 2011, Stolt [18] | 4                   | Retropertoneal bleeding | Treatment with surgical revision. | Expired after 2 days from worsening right cardiac failure. |
| 11 2012, Acharya [20] | 12                  | -                                                   | -                                                      | -     |
| 12 2012, Elbey [19] | 10,5                | Failure of removing the agglutinant pericardial effusion | Treatment with surgical revision | Yes, cardiogenic shock due to hemorrhagic pericardial effusion which was covered in a thick fibrinous peel. |
| 13 2013, Vatan [21] | 22                  | Post procedure long sinus arrest noted. | Atropine injection resolved the sinus arrest | yes, severe hemodynamic deterioration |
| 14 2014, Meier [22] | 10                  | -                                                   | -                                                      | -     |
| 15 2015, Tsai [23] | 19                  | -                                                   | -                                                      | -     |
| 16 2016, Saxena [16] | 6                   | -                                                   | -                                                      | -     |
| 17 2018, Dar [12] | 22                  | -                                                   | -                                                      | -     |
| 18 2019, Mohammed [24] | 10                  | -                                                   | -                                                      | -     |
| 19 2019, Singleton [25] | 8                   | -                                                   | -                                                      | -     |

bASO = Atrial septal occluder; a tPA= tissue plasminogen activator.